Skip to main content
. 2024 Mar 29;16(7):1343. doi: 10.3390/cancers16071343

Figure 1.

Figure 1

Neuroblastoma patients bearing a tumor with MYCN amplification or high MYCN mRNA levels show a poor prognosis. (A) Oncoprint of somatic mutations shows the genetic alterations and mRNA expression levels of MYCN, EGFR, EGF, MAPK1 and CTSD in pediatric NB patients (TARGET, 2018). (B) Scatter plots representing the correlations between MYCNCTSD (a), MYCN–EGFR (b), MYCNMAPK1 (c) and CTSD–MAPK1 (d) mRNA expression.